Entering text into the input field will update the search result below

BioCryst's Orladeyo reduces HAE attack rate by 80% over a period of 96 weeks

  • BioCryst Pharmaceuticals (NASDAQ:BCRX) announces that hereditary angioedema (HAE) patients who were randomized to receive 150 mg of oral, once-daily Orladeyo (berotralstat) at the start of the APeX-2 trial had an 80% average reduction in their mean attack rate per month during weeks 25-96 of the trial, compared

Recommended For You

About BCRX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BCRX--
BioCryst Pharmaceuticals, Inc.